Ali Khademhosseini, the shift toward preventive medicine, particularly with GLP-1s, reveals a powerful paradigm change in healthcare
They assessed participants clinical parameters, dietary intake, and eating behaviors at the start of the study, 3 months after the start, and 12 months after the start
ShedRxs published VIP-tier average is 9.8% of starting body weight
Diabetes indications are often treated differently from obesity indications
One small study showed participants consuming ACV lost slightly more weight than a control group over 12 weeks, but the difference amounted to about 2-4 pounds
Such investigations are essential for refining the clinical application of GLP-1R agonists and remain an important avenue for future research once suitable data become available